News - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

201 to 225 of 435 results

Abide Therapeutics in up to $430 million deal with Merck & Co for type 2 diabetes and metabolic disease

03-05-2013

Privately-held biopharma firm Abide Therapeutics has entered into a collaboration agreement with US…

Abide TherapeuticsDiabetesLicensingMerck & CoMetabolicsPharmaceuticalResearch

US Judge throws out verdict in Takeda Actos case

03-05-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Emisphere earns $10 million on amended deal with Novo Nordisk

30-04-2013

USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Takeda considering options over US Actos court ruling

29-04-2013

The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals (TYO 4502), says that in the case…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Brazil to resume human insulin production, with a $200+ investment

18-04-2013

The resumption of national human insulin production was announced in Brazil this week, at an event in…

Biomm TechnologyDiabetesFiocruzInsulinPharmaceuticalProductionSouth America

Lilly's diabetes drug dulaglutide does well in two additional trials

16-04-2013

US drug major Eli Lilly (NYSE: LLY) has released positive top-line results of two additional Phase III…

DiabetesdulaglutideEli LillyPharmaceuticalResearch

Eli Lilly views additional $180 million investment to expand insulin making in Indianapolis

02-04-2013

US pharma major Eli Lilly (NYSE: LLY) says that it is working closely with the City on a proposal to…

DiabetesFinancialInsulinLillyNorth AmericaPharmaceuticalProduction

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

EMA follows FDA lead, launching investigation on pancreatic risks with GLP-1-based type 2 diabetes drugs

27-03-2013

The European Medicines Agency says it is investigating findings by a group of independent academic researchers…

DiabetesEuropePharmaceuticalRegulation

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga

25-03-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Merck KGaA links with Bristol-Myers for Glucophage promotion in China

19-03-2013

German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Astellas files for Japanese approval of ipragliflozin for types 2 diabetes

14-03-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for…

Asia-PacificAstellas PharmaDiabetesipragliflozinPharmaceuticalRegulation

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

11-03-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

Anti-aging breakthrough could mean new drugs within five years

09-03-2013

Drugs that combat aging may be available within five years, following landmark work led by an Australian…

DiabetesGlaxoSmithKlineNeurologicalOncologyPharmaceuticalResearchresveratrol

Novo Nordisk debuts Tresiba in UK and Denmark

04-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has started the European roll-out of its Tresiba (insulin…

DiabetesEuropeMarkets & MarketingNovo NordiskPharmaceuticalTresiba

201 to 225 of 435 results

Back to top